Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensiv...(copeia.com target _new http://www.pharm...),Health

Date:5/16/2008

copeia.com" target="_new">http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.

(1) Prescribing Information for Coreg CR(R), Lotensin(R), Avapro(R),

Benicar(R) and Norvasc(R)

(2) American Heart Association news release.

http://americanheart.mediaroom.com/index.php?s=43&item=59. Accessed

April 7, 2008.

(3) AHA 2007 Heart Disease and Stroke Statistics, p. 3.

(4) Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the

Joint National Committee on Prevention, Detection, valuation, and

Treatment of High Blood Pressure. Journal of the American Medical

Association. 2003;289:p.2560-2572.

(5) American Diabetes Association: http://www.diabetes.org/utils/printthispage.jsp?PageID=STATISTICS_233192.

Accessed April 4, 2008.

(6) Diabetes Care, Volume 27, Supplement 1, January 2004.

(7) National Institute of Diabetes and Digestive and Kidney Diseases.

http://kidney.niddk.nih.gov/kudisease
'/>"/>

SOURCE Pharmacopeia Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis